Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer
Sung Gwe Ahn, Joon Jeong, Soon Won Hong, et al.
Journal of Pathology and Translational Medicine (2015) Vol. 49, Iss. 5, pp. 355-363
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Precision unveiled: Synergistic genomic landscapes in breast cancer—Integrating single‐cell analysis and decoding drug toxicity for elite prognostication and tailored therapeutics
Cheng‐Lu Jiang, Shengke Zhang, Lai Jiang, et al.
Environmental Toxicology (2024) Vol. 39, Iss. 6, pp. 3448-3472
Closed Access | Times Cited: 17
Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer
In Hye Song, Sun‐Hee Heo, Won Seon Bang, et al.
Cancer Research and Treatment (2016) Vol. 49, Iss. 2, pp. 399-407
Open Access | Times Cited: 123
Triple negative breast cancer – prognostic role of immune-related factors: a systematic review
Elisabeth Specht Stovgaard, Dorte Nielsen, Estrid Høgdall, et al.
Acta Oncologica (2017) Vol. 57, Iss. 1, pp. 74-82
Open Access | Times Cited: 119
An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer
Silei Sui, Xin An, Caiming Xu, et al.
Theranostics (2020) Vol. 10, Iss. 26, pp. 11938-11949
Open Access | Times Cited: 118
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)
Nobumoto Tomioka, Manabu Azuma, Mayuko Ikarashi, et al.
Breast Cancer (2017) Vol. 25, Iss. 1, pp. 34-42
Open Access | Times Cited: 98
Implications of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer: clinical oncologist perspectives
Mahira Lopes Rosa, Tomás Reinert, Maiane Maria Pauletto, et al.
Translational Breast Cancer Research (2024) Vol. 5, pp. 4-4
Open Access | Times Cited: 8
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility
Andrea Ravelli, Giandomenico Roviello, Daniele Cretella, et al.
Tumor Biology (2017) Vol. 39, Iss. 4, pp. 101042831769502-101042831769502
Open Access | Times Cited: 83
Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value
Ahrong Kim, So Jeong Lee, Young Keum Kim, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 69
Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression
Christophe Van Berckelaer, Charlotte Rypens, Peter A. van Dam, et al.
Breast Cancer Research (2019) Vol. 21, Iss. 1
Open Access | Times Cited: 65
Whole Slide Imaging for Analytical Anatomic Pathology and Telepathology: Practical Applications Today, Promises, and Perils
Alton B. Farris, C. M. S. Cohen, Thomas E. Rogers, et al.
Archives of Pathology & Laboratory Medicine (2017) Vol. 141, Iss. 4, pp. 542-550
Open Access | Times Cited: 58
Breast Cancer Immunology and Immunotherapy
Luis de la Cruz‐Merino, M. Chiesa, Rosalía Caballero, et al.
International review of cell and molecular biology (2016), pp. 1-53
Closed Access | Times Cited: 53
The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy
Ruonan Li, Lili Cao
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Lymphocyte count or percentage: which can better predict the prognosis of advanced cancer patients following palliative care?
Weiwei Zhao, Peng Wang, Huixun Jia, et al.
BMC Cancer (2017) Vol. 17, Iss. 1
Open Access | Times Cited: 42
The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status
Anna Glajcar, Joanna Szpor, Diana Hodorowicz‐Zaniewska, et al.
Virchows Archiv (2019) Vol. 475, Iss. 1, pp. 13-23
Open Access | Times Cited: 39

Anca Zgură, Laurentia Galesa, Elvira Brătilă, et al.
PubMed (2018) Vol. 13, Iss. 4, pp. 317-320
Closed Access | Times Cited: 37
Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes
Joo Young Kim, Sun‐Hee Heo, Seul Ki Choi, et al.
Virchows Archiv (2017) Vol. 470, Iss. 4, pp. 381-389
Closed Access | Times Cited: 33
The next level of 3D tumour models: immunocompetence
Agata Nyga, Joana B. Neves, Katerina Stamati, et al.
Drug Discovery Today (2016) Vol. 21, Iss. 9, pp. 1421-1428
Open Access | Times Cited: 27
Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models
Ana S. Leal, Kayla Zydeck, Sarah Carapellucci, et al.
npj Breast Cancer (2019) Vol. 5, Iss. 1
Open Access | Times Cited: 27
An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes
Ahrong Kim, Sun‐Hee Heo, Young‐Ae Kim, et al.
American Journal of Clinical Pathology (2016) Vol. 146, Iss. 1, pp. 137-144
Open Access | Times Cited: 26
Stromal tumor‑infiltrating lymphocytes evaluated on H&E‑stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma
Chungsu Hwang, So Hee Lee, Jung Eun Lee, et al.
Oncology Letters (2019)
Open Access | Times Cited: 24
<p>Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review</p>
Weilin Xu, Xiu Chen, Fei Deng, et al.
OncoTargets and Therapy (2020) Vol. Volume 13, pp. 5887-5899
Open Access | Times Cited: 21
Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor‐infiltrating lymphocytes (TILs) in breast cancer
Hee Jin Lee, Ahrong Kim, In Hye Song, et al.
Pathology International (2016) Vol. 66, Iss. 4, pp. 202-209
Closed Access | Times Cited: 22
Immune phenotype of patients with stage IV metastatic inflammatory breast cancer
Sandra V. Fernandez, Alexander W. MacFarlane, Mowafaq Jillab, et al.
Breast Cancer Research (2020) Vol. 22, Iss. 1
Open Access | Times Cited: 18
Using Self-Assembling ADDomer Platform to Display B and T Epitopes of Type O Foot-and-Mouth Disease Virus
Chaowei Luo, Quanhui Yan, Juncong Huang, et al.
Viruses (2022) Vol. 14, Iss. 8, pp. 1810-1810
Open Access | Times Cited: 10
Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma
Kyung Un Choi, Ahrong Kim, Jee Yeon Kim, et al.
Journal of Ovarian Research (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top